YTYan Zhi Tan

Yan Zhi Tan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yan Zhi Tan has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe

    by Yan Zhi Tan, Emily Breislin, Matthew Woods, Matthew Madin-Warburton, Daniel Gladwell, Alexandra Zang, Sachin Vadgama, Brett Doble, Adriana Wiesinger, Oriol Sola-Morales

    Despite clinical efficacy and cost-effectiveness, time to reimbursement for chimeric antigen receptor (CAR) T-cell therapies varies greatly across Europe. We examined these differences, and quantified potential patient benefits with faster access. A targeted literature search collated reimbursement statuses for all approved CAR T-cell therapy indications by 1 October 2024. Time to reimbursement decision (TTRD), defined as time between marketing authorization and published reimbursement decision, was assessed. By benchmarking against the TTRD of the three fastest countries, patient impact, in the form of potential gains in lives, life-years (LYs) and long-term survivors, for the first three approved indications for CAR T-cell therapies were estimated. Each outcome was multiplied by population size, incidence, CAR T-cell eligibility, and market share to obtain population-level impact. Scenario analyses were conducted by examining different TTRD assumptions. Across 12 identified indications for CAR T-cell therapy, France, Germany, and Switzerland had the fastest TTRD, compared to Denmark, the Netherlands, and Ireland which had the slowest. Among an estimated annual incident population of 6,594 across 3 L + diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and pediatric acute lymphoblastic leukemia (ALL), 1,199 lives, 1,222 long-term survivorships, and 37,229 LYs, could potentially be gained by ensuring time to access across these countries was equivalent to the fastest three assessors in these 3L + DLBCL, MCL, and pediatric ALL. Access to CAR T-cell therapies varied widely across European countries. Faster access to these therapies can result in significant health gains. Ensuring prompt and equitable access to innovative therapies requires proactive alignments between manufacturers and HTA bodies, possibly through mechanisms such alternative pricing models and risk-sharing agreements.


  • Open Access

    Cost-effectiveness analysis of intravascular ultrasound-guided peripheral vascular interventions in patients with femoropopliteal peripheral artery disease

    by Michael Lichtenberg, Jihad Mustapha, Yan Zhi Tan, Konstantinos Stavroulakis, Catherina Meijer, Henri Vanden Bavière

    Summary: Background: Intravascular ultrasound (IVUS)-guided percutaneous transluminal angioplasty (PTA) might offer clinical benefits compared to angiography-guided PTA in patients with peripheral artery disease (PAD). A cost-effectiveness model was developed to examine the benefits and costs of IVUS-guided PTA versus angiography-guided PTA in PAD patients with femoropopliteal (FP) occlusive disease. Methods: A two-step model (a one-year decision tree followed by a lifetime semi-Markov model) was developed from a German healthcare payer perspective to estimate the costs and outcomes over a one-year and lifetime horizon. Clinical events included target lesion revascularization (TLR), amputation, and death. Transition probabilities and utility values were derived from published literature. Healthcare costs were based on German Diagnosis Related Groups (DRG) codes. Costs and outcomes were discounted at a rate of 3% per year. The incremental cost-effectiveness ratio (ICER) was calculated, and sensitivity analyses were performed to assess the robustness of the results. Results: In the one-year horizon, IVUS-guided PTA resulted in incremental quality-adjusted life-years (QALY) and costs of 0.02 and €919 per patient respectively, with a corresponding ICER of €45,195/QALY gained versus angiography-guided PTA. In the lifetime horizon, IVUS-guided PTA outperforms angiography-guided PTA; it was associated with a cost saving of €46 per patient and incremental QALY of 0.22. Utility value for post-TLR, as well as probabilities of death and TLR had the greatest impact on the one-year ICER, while cost of TLR and probabilities of TLR and amputation influenced the lifetime ICER most. The probability of IVUS-guided PTA being cost-effective at a willingness-to-pay (WTP) threshold of €50,000/QALY was 50.4% in the one-year horizon and increased to 85.9% in the lifetime horizon. Conclusions: In this analysis IVUS-guided PTA among patients with symptomatic FP atherosclerosis was cost-saving in a lifetime horizon from the German healthcare payer perspective.


  • Burnout and resilience among pharmacy technicians: A Singapore study

    by Jin Jian Chong, Yan Zhi Tan, Lita Sui Tjien Chew, Kok Hian Tan, Aiwen Wang


  • Burnout and resilience among pharmacists: A Singapore study

    by Yan Zhi Tan, Jin Jian Chong, Lita Sui Tjien Chew, Kok Hian Tan, Aiwen Wang

    Background: Rising demand in healthcare in recent years has placed significant stress on healthcare professionals and has inevitably led to increasing levels of burnout. While associated factors and negative consequences of burnout have been quantified within various professions, there is a paucity of data describing its prevalence and impact among pharmacists, and within the Asia‐Pacific region.Objectives: To assess the prevalence of, and characterize risk factors, that may be associated with burnout among pharmacists in patient care sectors in Singapore.Methods: A cross‐sectional survey was conducted among pharmacists in patient care sectors in Singapore from February to April 2020. Participation invites to the survey were disseminated by pharmacy managers in patient care areas across all healthcare institutions in Singapore. The Maslach Burnout Inventory Human Services Survey (MBI‐HSS) was used to assess the prevalence of burnout in the respondent, and the Brief Resilience Scale (BRS) and Jefferson Scale of Physician Empathy (JSPE) to evaluate resilience and empathy respectively. Demographic characteristics were also collected and summarized. Multivariate logistic regression models were used to explore associations between burnout and potential risk factors. Possible impact from burnout was also assessed as part of the questionnaire. Burnout was defined as a high emotional exhaustion (EE, ≥27) or depersonalization (DP, ≥10) score on the MBI‐HSS.Results: Seven hundred and six out of 1289 pharmacists (54.8%) completed the survey, of which 61.5% of respondents experienced burnout. Factors associated with burnout included institution of practice, hours at work, number of patient care hours, resilience, and empathy. Pharmacists with burnout had a higher propensity to seek a job change, were less satisfied with work, and took more medical leave than non‐burnout counterparts.Conclusion: Burnout among Singapore pharmacists is prevalent and deserves attention. Comprehensive strategies are needed to mitigate the potential negative consequences that may arise from increasing levels of burnout.


  • Patient-Reported Outcome Measures in Registry-Based Studies of Type 2 Diabetes Mellitus: a Systematic Review

    by Yu Ting Chen, Yan Zhi Tan, Mcvin Cheen, Hwee-Lin Wee

    Patient-reported outcome measures (PROMs) and patient registries both play important roles in assessing patient outcomes. However, no study has examined the use of PROMs among registries involving patients with type 2 diabetes mellitus (T2DM). Our objective is twofold: first, to review the range of PROMs used in registry-based studies of patients with T2DM; second, to describe associations between these PROMs, T2DM and its complications.


  • Prevalence of and factors associated with primary medication non‐adherence in chronic disease: A systematic review and meta‐analysis

    by McVin Hua Heng Cheen, Yan Zhi Tan, Ling Fen Oh, Hwee Lin Wee, Julian Thumboo

    Background Primary medication non‐adherence (PMN), defined as failure to obtain newly prescribed medications, results in adverse clinical and economic outcomes. We aimed to (1) assess the prevalence of PMN in six common chronic diseases: asthma and/ or chronic obstructive pulmonary disease, depression, diabetes mellitus, hyperlipidemia, hypertension and osteoporosis; (2) identify and categorize factors associated with PMN; (3) explore characteristics that contributed to heterogeneity between studies. Methods We performed a systematic search in MEDLINE, Embase, Cochrane Library, CINAHL, and PsycINFO. Studies published in English between January 2008 and August 2018 assessing PMN in subjects aged ≥18 years were included. We used the Cochrane risk of bias tool, Newcastle‐Ottawa Scale and National Heart, Lung and Blood Institute Quality Assessment Tool to assess the quality of randomized controlled trials, cohort and cross‐sectional studies respectively. Findings were reported using the PRISMA checklist. PMN rates were pooled using a random‐effects model. We summarised factors associated with PMN descriptively. Subgroup analysis was performed to explore sources of heterogeneity. Results We screened 3,083 articles and included 33 (5 randomized controlled trials, 26 cohort and 2 cross‐sectional studies, n=539,156), of which 31 (n=519,971) were used in meta‐analysis. The pooled PMN rate was 17% (95% CI: 15–20%). Pooled PMN rates were highest in osteoporosis (25%, 95% CI: 7–44%) and hyperlipidemia (25%, 95% CI: 18–32%), and lowest in diabetes mellitus (10%, 95% CI: 7–12%). Factors commonly associated with PMN include younger age, number of concurrent medications, practitioner specialty and higher co‐payment. Type of chronic disease, age, study setting and PMN definition contributed to heterogeneity between studies (all p<0.001). Conclusion Primary medication non‐adherence is common among patients with chronic diseases and more needs to be done to address this issue in order to improve patient outcomes. Future PMN studies could benefit from greater standardization to enhance comparability.


  • Open Access

    Health-related quality of life of patients with inflammatory bowel disease in Singapore

    by Prisca Yue Min Ho, Wenjia Hu, Ying Yun Lee, Chuxi Gao, Yan Zhi Tan, Hua Heng Cheen, Hwee Lin Wee, Teong Guan Lim, Wan Chee Ong

    Inflammatory bowel disease (IBD) is associated with considerable impairment of patients' health-related quality of life (HRQoL). Knowledge of factors that significantly affect IBD patients' HRQoL can contribute to better patient care. However, the HRQoL of IBD patients in non-Western countries are limited. Hence, we assessed the HRQoL of Singaporean IBD patients and identified its determinants. A prospective, cross-sectional study was conducted at Singapore General Hospital outpatient IBD Centre. The HRQoL of IBD patients was assessed using the short IBD questionnaire (SIBDQ), Short Form-36 physical and mental component summary (SF-36 PCS/MCS) and EuroQol 5-dimensions 3-levels (EQ-5D-3L) and visual analogue scale (VAS). Independent samples t-test was used to compare HRQoL between Crohn's disease (CD) and ulcerative colitis (UC). Determinants of HRQoL were identified through multiple linear regression. A total of 195 IBD patients (103 UC, 92 CD) with a mean disease duration of 11.2 years were included. There was no significant difference in HRQoL between patients with UC and CD. Factors that significantly worsened HRQoL were presence of active disease (b=-6.293 [SIBDQ], -9.409 [PCS], -9.743 [MCS], -7.254 [VAS]), corticosteroids use (b=-7.392 [SIBDQ], -10.390 [PCS], -8.827 [MCS]), poor medication adherence (b=-4.049 [SIBDQ], -1.320 [MCS], -8.961 [VAS]), presence of extraintestinal manifestations (b=-13.381 [PCS]), comorbidities (b=-4.531 [PCS]), non-employment (b=-9.738 [MCS], -0.104 [EQ-5D-3L]) and public housing (b=-8.070 [PCS], -9.207 [VAS]). The HRQoL is impaired in this Asian cohort of IBD. The magnitude of HRQoL impairment was similar in UC and CD. Clinical characteristics were better determinants of patients' HRQoL than socio-demographic factors. Recognizing the factors that impact patients' HRQoL would improve the holistic management of IBD patients.


  • Trends in medication utilization, glycemic control and outcomes among type 2 diabetes patients in a tertiary referral center in Singapore from 2007 to 2017

    by Yan Zhi Tan, McVin Hua Heng Cheen, Su‐Yen Goh, Yong Mong Bee, Paik Shia Lim, Giat Yeng Khee, Julian Thumboo

    Background: Use of glucose‐lowering agents is a cornerstone in combating type 2 diabetes (T2DM). Treatment guidelines have changed significantly over the past decade. We report temporal trends in medication utilization, glycemic control and rate of severe hypoglycemia in T2DM patients at a tertiary referral center in Singapore.Methods: We analyzed data of 36 924 T2DM patients seen at Singapore General Hospital from 2007 to 2017. Annual age‐, sex‐ and racially‐standardized proportions of patients (a) prescribed with each class of glucose‐lowering agent, (b) on various glucose‐lowering regimens, and (c) had an HbA1c of less than 6%, 6% to less than 7%, 7% to less than 8%, 8% to less than 9%, or 9% or more were estimated using logistic regression. Poisson regression was used to estimate standardized rate of severe hypoglycemia.Results: From 2007 to 2017, use of metformin (45.9% to 59.6%) and insulin (24.4% to 57.9%) increased, while utilization of sulfonylureas (52.0% to 44.9%) decreased (all P < 0.001). Utilization of dipeptidyl peptidase‐4 inhibitors (1.2% to 31.2%) and sodium‐glucose cotransporter‐2 inhibitors (0.5% to 7.4%) increased from 2008 to 2017 and 2012 to 2017, respectively (all P < 0.001). More patients were prescribed a combination of insulin and oral agents (17.3% to 46.0%, P < 0.001). The proportion of patients with HbA1c of 8% or more increased (33.7% to 36.0%, P < 0.001). Rates of severe hypoglycemia (5.0 to 8.4 per 100 patient‐years, P < 0.001) also rose.Conclusion: Medication utilization patterns have changed significantly over the past 11 years with a shift towards newer agents. Glycemic control has remained stable, and rate of severe hypoglycemia increased. Further analysis is required before causal relationships can be inferred.